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Introduction
Cinaciguat (BAY 58-2667) is an nitric oxide (NO)-inde-
pendent and heme-independent soluble guanylate
cyclase (sGC) activator. Cinaciguat preferentially acti-
vates sGC in its oxidized or heme-free state, when the
enzyme is insensitive to its endogenous ligand NO and
exogenous nitrovasodilators [1].
Endothelium-derived NO is one of the mechanisms by
which platelet aggregation and thrombus formation is
prevented by the intact blood vessel wall. Pharmacologi-
cal stimulation of sGC in platelets correlates with inhibi-
tion of aggregation, platelet cGMP increase, prolongation
of bleeding time and antithrombotic effects in vitro [2].
This protective mechanism may be impaired in vascular
disease and impaired NO availability. Thus, sGC activa-
tors may have antithrombotic effects similar to endogen-
ous NO. Indeed, cinaciguat potently inhibited platelet
aggregation induced by the thromboxane mimic U46619
and collagen and prolonged rat-tail bleeding time up to
2-fold [3]. Thus, in vitro data suggested that coadminis-
tration of cinaciguat and aspirin may increase the antipla-
telet effects of aspirin and could result in bleeding.
Methods
This non-randomized, open-label trial was conducted
from September to November 2001 in a single center in
Germany. It was carried out in accordance with the
Declaration of Helsinki and adhered to the International
Conference of Harmonization good clinical practice
guidelines and the German drug law (AMG). The study
protocol was approved by the Ethics Committee of the
North-Rhine Medical Council, Duesseldorf, Germany.
The study consisted of a 9-day treatment phase with
100 mg oral acetylsalicylic acid (aspirin) once daily
administered in the morning in the fasting state and,
after the last dose of aspirin, four sequential oral doses
of 1.5 mg cinaciguat administered in the fasting state at
1-hour intervals. The first dose of cinaciguat was admi-
nistered together with the last dose of aspirin. This cina-
ciguat dosing schedule was used to mimic a prolonged
plasma concentration over time profile.
Results
12 healthy men (mean age, 32.4 years, range, 23 - 42
years) were enrolled and completed the study according
to protocol.
Low-dose aspirin treatment in healthy subjects
resulted in the expected inhibition of platelet aggrega-
tion. 4 oral doses of 1.5 mg cinaciguat administered at
1-hour intervals did not significantly affect platelet
aggregation induced by collagen and the thromboxane
A2 mimetic U 46619 or bleeding time. These results are
in line with the findings of a single dose escalation
study.
Plasma pharmacokinetics of cinaciguat following 4
oral doses of 1.5 mg cinaciguat administered at 1-hour
intervals showed pronounced inter-individual variability.
There was no major pharmacokinetic interaction
detected between aspirin and cinaciguat, compared with
the data of a previous study, which applied the same
dosing regimen.
Conclusion
Coadministration of cinaciguat and aspirin did not
reveal any pharmacodynamic interaction with respect of
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